Glucotrack, Inc. Director Resigns Over Potential Conflict

What Happened

• Glucotrack, Inc. (GCTK) filed a Form 8‑K reporting that director Paul V. Goode resigned from the Board effective immediately on September 14, 2026.
• Mr. Goode stated his resignation was based on his conclusion that a potential conflict of interest exists between Glucotrack and its subsidiary in connection with ongoing discussions about implementing the duties, rights and obligations under the merger agreement that completed the Company's business combination with Lokahi Therapeutics, Inc.
• The company provided Mr. Goode with a copy of the disclosures and gave him the opportunity to submit a letter indicating whether he agrees with the company’s statements.

Key Details

• Resignation date: September 14, 2026 (effective immediately).
• Director: Paul V. Goode.
• Reason given: potential conflict related to implementation of post‑merger duties/rights involving Glucotrack and its subsidiary under the Lokahi transaction.
• Filing: Current Report on Form 8‑K filed September 18, 2026.

Why It Matters

• Board composition and governance: an unexpected director departure can affect board dynamics and oversight, which investors watch for corporate governance stability.
• Merger implementation: the resignation specifically cites issues tied to implementing terms of the Lokahi Therapeutics merger; this highlights active governance or contractual matters that could be relevant to ongoing integration or subsidiary oversight.
• No financial results or officer replacements were reported in this filing; the company did not announce a replacement director in the 8‑K.